Abstract Development of effective counteragents against the novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome 2 (SARS-CoV-2) strains, requires clear insights and information for understanding immune responses associated with it. This global pandemic has pushed healthcare system restricted movement people succumbing available therapeutics utterly warrants developme...